

AD_____

Award Number: W81XWH-10-1-0352

TITLE: Development of a Combination Therapy for Prostate Cancer by Targeting Stat3 and HIF-1alpha

PRINCIPAL INVESTIGATOR: Najjie Jing, Ph.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine
Houston, TX 77030

REPORT DATE: July 2013

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) July 2013		2. REPORT TYPE Final		3. DATES COVERED (From - To) 1 July 2010 - 30 June 2013	
4. TITLE AND SUBTITLE Development of a Combination Therapy for Prostate Cancer by Targeting Stat3 and HIF-1alpha				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-10-1-0352	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Naijie Jing E-Mail: njing@bcm.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine Houston, TX 77030				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT It is becoming increasingly evident that improving the cure rate of many cancers will require treatment regimens hit more than one validated tumor targets. Developing an anti-cancer agent that targets two oncoproteins simultaneously is a promising strategy for accomplishing this goal. It would be expected to promote drug efficacy, reduce therapy-resistant without introducing additional toxic side effects. Recently, we have identified TEL03 from Chinese medicinal herb significantly inhibits activations of HIF-1α/2α and phosphorylated Stat3 (p-Stat3), and blocks the expression of their down-regulated oncogenes (e.g. Bcl2, VEGF, Glut1, and others) in cancer cells. TEL03 also dramatically suppressed the growth of prostate, breast and pancreatic tumors in xenograft models. Our previous studies provided evidence that targeting both HIF-1α and Stat3 together could improve tumor response to either agent alone, and reduce drug resistance and treatment failure. TEL03 was showed inhibition of tumor growth and a marked delay in tumor re-growth, and demonstrated a greater-than-expected in vivo potency. Our results also provided evidence that TEL03 has potential to be a potent anti-cancer agent for pancreatic cancer therapy, suggesting that TEL03 could have a possible clinical application in prostate cancer therapy.					
15. SUBJECT TERMS Stat3, HIF-1alpha, TEL03, cancer therapy, Prostate cancer.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	19	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Cover page.....	1
SF268.....	2
Introduction.....	4-5
Key Research Accomplishments.....	5-11
Conclusion.....	11
Overall Project Summary.....	11-12
Project Outcomes.....	12
References.....	12-14
Appendices (PI CV).....	15-19

ANNUAL REPORT FOR PC093258 (W81XWH-09-PCRP-IDA)

PI: Naijie Jing

A. INTRODUCTION

A1. Title: Developing a novel agent to target HIF-1 α and Stat3 is important for prostate cancer therapy

A2. Significance

Prostate cancer is the most common cancer in men worldwide, accounting for approximately 242,000 new cases and 28,000 deaths annually in the USA. Although localized disease is often curable, advanced disease is generally not, especially when the cancer becomes castration resistant (mCRPC) and metastasizes. Docetaxel-based cytotoxic chemotherapy is most common therapy for mCRPC (1). Most prostate cancer (PC) patients are treatable, but the patients usually die due to drug resistance and metastatic disease (2). Hypoxia is one of the fundamental biological phenomena that are intricately associated with the development and aggressiveness of a variety of solid tumors including prostate cancer. Tumour hypoxia is progressively emerging as a common feature of prostate tumours associated with poor prognosis (3). HIF-1 is the only DNA regulatory element truly regulated by oxygen. Cross-talk between the AR and HIF-1 α in prostate cancer cells has recently been identified (4).

HIF-1 protein is a heterodimer consisting of two subunits: HIF-1 α and HIF-1 β . Under normoxia, prolyl hydroxylases (PHDs) hydroxylate the prolyl residues of HIF-1 α at amino acids P402 and P564, which are then recognized by VHL (Von Hippel-Lindau) and targeted to the ubiquitin proteasome pathway. An additional hydroxylation at N803 blocks the binding of p300 and CBP (Creb-binding protein) to HIF-1 α and inhibits HIF-1-mediated gene transcription. Under hypoxia, HIF-1 α is not hydroxylated and not degraded. The unmodified protein then dimerizes with HIF-1 β . As N803 is not hydroxylated, p300 (or CBP) can bind to HIF-1 α , allowing transcriptional activation of HIF-1 target genes, which are included more than 70 putative hypoxia-inducible genes, to date, and involved in many cell processes including glucose metabolism, erythropoiesis, angiogenesis, anti-apoptosis, metastasis, and other functions (5-10). HIF-1 α was demonstrated to overexpress in many human cancers, including prostate cancer (11-13). Overexpression of HIF-1 α not only strongly enhances the tumor growth rate and metastatic potential, but also contributes to resistance to radiotherapy and chemotherapy, leading to treatment failure and increase in patient mortality (14, 15).

Stat3 (signal transducer and activator of transcription 3) exist as monomers or N-terminal head-to-head dimers in the cytoplasm (16,17). When stimulated by cytokines or growth factors, such as JAK, Src or EGFR (18, 19), Stat3 is activated upon phosphorylation on tyrosine residue Y705 (20). Tyrosine phosphorylation induces formation of a parallel dimer through their SH2 domains (18, 20). The activated dimers translocate to the nucleus, where they bind to DNA-response elements in the promoters of target genes and activates transcription. Stat3 participates in oncogenesis through the upregulation of genes encoding anti-apoptosis (Bcl-x_L, Bcl-2, Mcl-1, and survivin), cell-cycle regulators (cyclin D1 and c-myc), and inducers of angiogenesis (VEGF) (14, 24, 25). Also, immune system plays a crucial role in controlling tumor incidence and growth. Stat3 signaling is a major intrinsic pathway of cancer inflammation and mediates the cancer-promoting properties. Stat3 suppresses anti-tumor immune responses and promotes inflammation-induced cancer, making it an attractive target (25-27).

A3. Innovation

1. TEL03 is a novel anti-cancer agent from Chinese herbal medicine (CHM) that targets HIF-1 α /2 α and Stat3. Recently, we have identified a perylene derivative TEL03 from *hypocrellin* (CHM: *Hypocrella bambusae*) targets HIF-1 α /2 α and Stat3, significantly inhibits activations of HIF-1 α /2 α and phosphorylated Stat3 (p-Stat3), and blocks the expression of their down-regulated oncogenes (e.g. Bcl2, VEGF, Glut1, and others) in cancer cells. TEL03 also can significantly suppress the growth of prostate and pancreatic tumors in xenograft models. Our previous studies (28) provided evidence that

targeting both HIF-1 α and Stat3 together could improve tumor response to either agent alone, and reduce drug resistance and treatment failure. Stat3 (signal transducer and activator of transcription 3) participates in oncogenesis through the upregulation of genes encoding anti-apoptosis, cell-cycle regulators, and inducers of angiogenesis in many cancers, including breast cancer (29-31). Also, immune system plays a crucial role in controlling tumor incidence and growth. Stat3 signaling is a major intrinsic pathway of cancer inflammation and mediates the cancer-promoting properties. Stat3 suppresses anti-tumor immune responses and promotes inflammation-induced cancer, making it as a critical target for cancer therapy (32,33). Our results showed that TEL03 as a dual inhibitor can promote drug efficacy, reduce emergence of therapy-resistant cancer cells, and decrease the incidence of cancer relapse with a low toxicity.

2. Extracting new anti-cancer compounds from CHM is a pioneering strategy. Although anti-cancer agents have developed quickly, new anti-cancer agents are still urgently required. The advantages of TEL03 provide evidence that it is a pioneer strategy to develop a promising anti-cancer agent from new compounds that are extracted from CHM. CHM is a major aspect of traditional medicine, which has been developed as part of Chinese culture since 200 BC. CHM, which is mainly obtained from nature plants (~95%), focuses on restoring a balance of energy, body, and spirit to maintain health rather than treating a particular diseases or medical condition. Also, they can help ease the side effects of standard cancer treatment, control pain, improve quality of life, strengthen the immune system, and in some cases, stop tumor growth and spread. With collaborating with Dr. Yuan group in Peking University (China), we have extracted many compounds from CHM, which mostly are new compounds without previously studied, and discovered few compounds that activity against the molecular target: HIF-1 α , such as a perylene derivative TEL03 derived from *hypocrellin* and NDT extracted from roots of *Zanthoxylum nitidum* (see below). Therefore, we propose to develop potent anti-cancer agents from CHM that targets HIF-1 α for prostate cancer therapy.

B. KEY RESEARCH ACCOMPLISHMENTS

B1. Extracting chemical compounds from CHM. In order to develop novel anti-cancer agents, we have extracted many compounds from CHM, such as: *Nitidine chloride (NDT) from Roots of Zanthoxylum nitidum (Fig.B1)*. The air-dried powdered roots of *Z. nitidum* (1Kg) were extracted with ethanol (95%, v/v, 3 $\times$ 5L) under reflux for 3 $\times$ 3h. The ethanol extract (15L) was subjected to cation exchange resins CC (gradient saturated sodium hydroxide in 60-90% ethanol) to afford an eluent contained nitidine chloride depending on the TLC behavior comparison with authentic sample. The solution contained nitidine chloride was concentrated under reduced pressure with a rotary evaporator to produce a total alkaloids deposit. The solution contained nitidine chloride was concentrated under reduced pressure with a rotary evaporator to produce a total alkaloids deposit.

B2. Drug synthesis based on the derivatives from hypocrellin. TEL03 as a lead compound was chemical synthesized based on perylene, which was derived from *hypocrellin* (Fig.B2a).

The method of synthesis The TEL03 was synthesized by the reaction that 0.2g (0.51mmol) of 3,4,9,10-perylenetetracarboxylic dianhydride was dissolved in 30mL n-Butanol heating to 90 $^{\circ}$ C and 0.8mL (6.3mmol) of 3-(dimethylamino)propylamine was added to the mixture, then kept the temperature for 4h. Cooling the mixture to




Fig.B1. NDT extracted from *Z. nitidum*




Fig.B2a. TEL03 is a derivative of perylene, which is original derived from hypocrellin.




Fig.C2b. The spectra of $^{13}\text{C-NMR}$ (A) and MS (B) for the synthesized TEL03.

room temperature, the precipitation was collected, and washed by chloroform and methanol. The molecular structure and purification of TEL03 were identified by ^1H -NMR, ^{13}C -NMR and Mass Spectrum (Fig.B2b). The HPLC results also showed that the purity of TEL03 is higher than 98%. Then, 0.1g (0.18mmol) TEL03 was mixed with 2mL methanol heating to 60°C , and 2mL solution of saturated hydrochloric acid in acetic ether was added to the mixture. After cooling down, the precipitation was washed by ethyl acetate.

B3. Screen for novel anti-cancer agents. The pathways: HIF-1 and Stat3 have been demonstrated to be important targets for breast cancer therapy (31). To determine whether each compound has potential to suppress the activation of HIF-1 α or Stat3 in cancer cells, the assay of western blot was employed to screen all the molecules in $10\mu\text{M}$ concentration. Since our previous experiments showed if adding $10\mu\text{M}$ concentration of a compound in cell cultures, this compound still can not inhibit the targeted molecules, thus, it cannot be an active drug. After screened more than 24 compounds extracted from CHM, we found that the molecules NDT (#2) and TEL03 (#5) have ability to inhibit HIF-1 α expression in cancer cells under hypoxia. Meantime, TEL03 also showed the inhibition of phosphorylated Stat3 (p-Stat3) without blocking total Stat3 (T-Stat3), which is mainly composed of unphosphorylated Stat3. Thus, TEL03 can inhibit the activation of both Stat3 and HIF-1 α (Fig.B3).




Fig.B3. Screening the compounds for HIF-1 α inhibitor under hypoxia (A) and p-Stat3 inhibitor (B) in MDA-MB-231 (note: N means normoxia).

B4. TEL03 selectively targets HIF-1 α and Stat3. Comparing the screen data of NDT (#2) with TEL03 (#5), we selected TEL03 as a first candidate to further study. Here we performed immunoblotting assay using human cancer cells, including breast, pancreatic, ovarian and other cancer cells to confirm TEL03 drug activity and selectivity. The results showed (Fig.B4) that TEL03 significantly inhibits the expressions of both HIF-1 $\alpha/2\alpha$ and p-Stat3 in breast cancer cells under normoxia and hypoxia environments. The IC₅₀s of inhibition of HIF-1 $\alpha/2\alpha$ and p-Stat3 for TEL03 are $\sim 3\mu\text{M}$ in breast cancer cells. TEL03 also inhibited the expression of the down-regulated protein Bcl2 under both normoxia and hypoxia. Importantly, TEL03 did not inhibit upstream proteins: JAK, SCR, and the most conservative proteins: p-Stat1, p-Stat5 and total Stat3 in Stat signaling, and also did not inhibit the critical proteins in HIF-1 signaling: p300 and HIF-1 β as well. Also we have checked off-target effects in other pathways, including AKT and ERK, TEL03 did not show inhibition to p-AKT and p-ERK (Fig.B4). Therefore, TEL03 has a selective target HIF-1 α and Stat3 in this range.




Fig.B4. TEL03 inhibits both HIF-1 $\alpha/2\alpha$ and Stat3 (N: normoxia, in which HIF-1 α is rapidly degraded by ubiquitin-proteasome).

B5. The mechanism of TEL03 inhibiting HIF-1 α and Stat3

(1) TEL03 directly targets both HIF-1 α and Stat3. To identify whether TEL03 inhibits HIF-1 α through the inhibition of Stat3 or TEL03 directly inhibits HIF-1 α , the two assays were employed: (1) under hypoxia we used T40214 that is a developed Stat3 inhibitor (34,35) to inhibit p-Stat3 in cancer cells, and then after 3 hours added TEL03 to detect whether TEL03 can inhibit HIF-1 α in the sample without p-Stat3; and (2) we performed qRT-PCR to measure RNA levels of HIF-1 α since if TEL03 inhibits HIF-1 α activity through the inhibition of Stat3, TEL03 should strongly suppress the RNA expression of HIF-1 α . Fig.B5A showed that T40214 totally inhibited p-Stat3 activity but did not inhibit HIF-1 α . HIF-1 α was totally inhibited after adding TEL03, showing that TEL03 directly suppresses HIF-1 α expression in the absent of p-Stat3. Also, the PCR data demonstrated (Fig.B5B) that TEL03 does not suppress the RNA level of HIF-1 α in cancer cells, suggesting that TEL03 inhibits HIF-1 α by targeting HIF-1 α protein in hypoxic cells.




Fig.B5. (A) Western blot showed that in hypoxia p-Stat3 was totally inhibited by T40214 (lanes 4 and 5) and HIF-1 α was only inhibited by adding TEL03 (lane 5). (B) qRT-PCR data showed that TEL03 did not suppress mRNA level of HIF-1 α in cancer cells.

(2) The mechanism of TEL03 inhibiting HIF-1 α . A GST pull-down assay was employed to determine the whether TEL03 specifically interacts with HIF-1 α protein. Fig.B6A shows that p300 did not bind with GST (lane1). The samples of GST- HIF-1 α /p300 and GST-HIF-1 α /p300+TEL03 have an equal level of HIF-1 α proteins (lanes2&3); however, the level of p300 in lane 3 is much less than that in lane 2. These results clear demonstrated that p300 strongly binds with HIF-1 α in hypoxia (lane2) and TEL03 directly interacts with HIF-1 α protein and blocks the binding interaction between HIF-1 α and p300 (lane3).




Fig.B6. (A) The pull-down data (B) The data shows that TEL03 greatly induce HIF-1 α degradation through proteasome in hypoxic cells (MG132 is an inhibitor of proteasome). (C) The distribution of H-bonds that formed between TEL03 and the C-terminal domain of HIF-1 α . The H-bonds were highly concentrated in the region of amino acids 796 to 801 (61%).

To determine whether TEL03 can promote the proteasomal degradation of HIF-1 α in hypoxic cells, cancer cells (MDA-MB-468) were exposed to TEL03 alone or TEL03 plus MG132, which is an inhibitor of proteasome, at 1% O₂ for 18 hrs. Comparing the hypoxia-induced levels of HIF-1 α with MG132 (proteasome blocked) and without MG132 (proteasome activated), the results demonstrated that TEL03 greatly induce the degradation of HIF-1 α through proteasome in hypoxic cells (Fig.B6B).

To gain insight in the molecular interaction between TEL03 and HIF-1 α , we randomly docked each TEL03 1000 times onto the C-terminal domain of HIF-1 α (36) without setting any constraints and then analyzed the distribution of hydrogen (H) bonds formed between each TEL03 and HIF-1 α because H-bonds play an important role in governing the interaction between HIF-1 α and TEL03. The analysis showed that the hydrogen bonds formed between TEL03 and the C-terminal domain of HIF-1 α were




Fig.B7. Structure of TEL03 binding in the region of residues of 709 to 801 of HIF-1 α in hypoxia.

highly concentrated in the region of amino acids 796 to 801 (61%) (Fig.C6C). Binding energy of TEL03 into the residues 796 to 801 in C-terminal of HIF-1 α is about -52 kcal, leading to the stable binding complex of HIF-1 α and TEL03 (Fig.B7). Combined all together, it suggests that TEL03 can bind in the range of residues 796 to 801 of HIF-1 α to block the interaction between p300 and N803 of HIF-1 α for transcription and then induce the proteasomal degradation of HIF-1 α in hypoxic cells.

(3) TEL03 disrupts Stat3 phosphorylation. First, the time-dependent western showed (Fig.B8A) that TEL03 significantly inhibited phosphorylated Stat3 (p-Stat3) activity in 30 mins but did not inhibit total Stat3 (T-Stat3), JAK2, and SRC kinases within 6 hours. This result provided evidence that TEL03 blocks Stat3 phosphorylation. Then we performed SPR (surface plasmon resonance) based binding assay to determine whether TEL03 has ability to block Stat3 phosphorylation by interrupting the EGFR ligand binding to Stat3. Previous studies identified that the residues of K591, R609, S611, E612, S613, E638, and Y640 in Stat3 SH2 domain form a pocket binding with the ligand motif of EGFR (e.g. pYxxx-ligand motif) (37,38). The biotinylated pYxxx-ligand motif (pY-1068: LPVPE(pY)INQSVP) was first immobilized on a streptavidin coated sensor chip (39,40). Then adding Stat3 alone and Stat3+TEL03 complex into the chip, we observed that increasing TEL03 reduced the binding possibility between Stat3 and the peptides, demonstrating that TEL03 interrupted the peptide receptor binding to Stat3 for phosphorylation (Fig.B8B). The modeling structure of TEL03/Stat3 complex, which was built from docking calculation using energy minimization and molecular dynamics under AMBER force fields described previously, predicted that TEL03 has potential to bind with the residues of E612, S613 and E638 in SH2 domain and disrupts the binding interaction between Stat3 and the phosphotyrosine-stimulating receptor (Fig.B8C).

(4) TEL03 inhibits VEGF, GLUT1 and induces apoptosis. Expression of VEGF, which is a key stimulator of angiogenesis, and GLUT1, which can increase intracellular glucose uptake, are hypoxia-upregulated by HIF-1-dependent transcriptional activation (41). The results of quantitative RT-PCR showed that TEL03 significantly suppressed the expressions of VEGF and GLUT1 mRNA in responding to hypoxia (Fig.B9A). Also, MTT was employed to determine the activities of inducing cancer cell apoptosis for TEL03. The results showed that TEL03 significantly induced apoptosis in breast cancer cells (MDA-MB-468 and MDA-MB-231) (Fig.B9B).

(5) Initial toxicity tests for TEL03. We also employed MTT to test whether TEL03 induces toxicity in normal breast cells (MCF10A). After adding TEL03

in breast epithelial cells (MCF10A) 48 hours, the data were collected under the same experimental




Fig.B8. (A) Time dependent western blot. (B) SPR data. (C) The molecular modeling of TEL03 interacting with the residues of E612, S613 and E638 in Stat3.




Fig.B9. (A) The mRNA levels of VEGF and GLUT1 was significantly suppressed by TEL03 in responding to hypoxia. (B) TEL03 induced apoptosis in MDA-MB-468 and MDA-MB-231 as well.




Fig.B10. MTT data from epithelial cells (MCF10A).

condition in breast cancer cells. TEL03 did not induce cell death in normal epithelial cells due to low expression of HIF-1 α and p-Stat3 in epithelial cells, suggesting that TEL03 has a favorable safety profile (Fig.B10).

(6) Summary. Our results provided solid evidence that (1) in hypoxia TEL03 directly bound in the region of residues 796 to 801 of HIF-1 α without disrupting HIF-1 β and p300, blocked the interaction between p300 and residue N803 of HIF-1 α and promoted the proteasomal degradation of HIF-1 α , interrupted HIF-1 α transcriptional activity, and greatly reduced the levels of hypoxia-regulated genes, including VEGF, GLUT1 and others (Fig.B11B). (2) TEL03 interacted with residues E612, S613 and E638 within the SH2 domain of Stat3 and disrupted Stat3 phosphorylation without interrupting the activations of p-Stat1 or p-Stat5, leading to decreased cancer cell proliferation, increased apoptosis, and reduced angiogenesis (Fig.B11A).




Fig.B11: (A) Mechanism of TEL03 inhibiting Stat3 activity. (B) Mechanism of TEL03 blocks HIF-1 α transcription.

B6. TEL03 drug efficacy in prostate cancer

It is clear that a single prostate tumor may contain a group of cancer cells, and instead of the current “one-size-fits-all” treatment approach, a combined therapeutics is needed to target each cell group. HIF-1 α and Stat3 are key factors that activates in all types of prostate cancers. TEL03 could be a potent candidate for future combination treatment in prostate cancer patients. Fig.B12 showed that TEL03 inhibited HIF1 α /2 α in PC3 and inhibited both HIF-1 α /2 α and p-Stat3 in DU145. We did not detect the expression of Stat3 and p-Stat3 in PC3 cells. Also, we performed in vivo assay to determine the drug efficacy of TEL03 using paclitaxel for comparison (Fig.13 & 14; Table). We gave the drug: TEL03 (2mg/kg) and paclitaxel (10mg/kg) every other day for two weeks. The results demonstrated that TEL03 significantly suppressed PC3 tumor growth. The tumors in untreated mice grew from 258 to 1582 mm³; TEL03 suppressed the tumors from 245 to 235 mm³ in two weeks. The results demonstrated that TEL03 significantly suppressed PC3 tumor growth.




Fig.B12. (A) TEL03 inhibits HIF1 α /2 α in PC3 and IC₅₀ = 1.8 μ M; no Stat3 is detected in PC3. (B) TEL03 inhibits both HIF-1 α /2 α and p-Stat3 in DU145 and IC₅₀s are 3~5 μ M.




Fig.B13. (A) Plot of PC tumor volume vs. day of treatment.

C. Pictures of animal treatment




Fig.B14. Left panel: untreated mice and right panel: TEL03 (2mg/kg) treated mice

B. Table of *in vivo* results

Group	Drug dose	No. of mice		Weight of mice (g)		Tumor (mm ³)		Fold of tumor-growth	Mean-tumor weight (g)	P value
		Start	End	Start	End	Start	End			
Control	untreated	5	5	27.0±0.6	25.5±1.8	258.0 ± 9	1582 ± 48	6.1	1.6 ± 0.1	-----
Paclitaxel	10mg/kg	5	5	29.7±0.7	27.5±1.3	254.4 ± 26	507 ± 64	2.0	1.0 ± 0.1	p<0.05
TEL03	2mg/kg	5	5	27.2±0.3	26.1±1.1	245.5 ± 15	235 ± 25	-0.1	0.5 ± 0.05	p<0.001

B7. *In vivo* drug efficacy in breast and pancreatic tumors

We have used the mice bearing breast (MDA-MB-231) and pancreatic (PANC1) tumors to inspect the ability of anti-cancer therapeutics of TEL03. After few days the tumors grew over 200mm³, mice were randomly assigned to several groups (each group has seven mice) for drug treatments. We gave drugs to each mouse every other day for 10 days (6 treatments) (red arrows) through IP injection or oral route.

(1) The mice bearing breast tumors were treated in five groups: (i) non-treated; (ii) treated by a control agent TEL01 (2mg/kg), which shows no inhibition of both HIF-1 α and Stat3 in Fig.B4 (#14); (iii) treated by T40214/PEI (10mg/kg), which is a Stat3 inhibitor delivered by PEI (2.5mg/kg) (34,35); (iv) treated by TEL03 (2mg/kg); and (v) oral treatment of TEL03 (5mg/kg). The results demonstrated (Fig.B14A) that without treatment the breast tumors grew aggressively to ~1860mm³ in 15 days. TEL01 shows no drug activity. The growth of breast tumors was strongly suppressed by T40214 and TEL03 (p<0.001). The oral treatment of TEL03 also showed some drug activity (p<0.02). Comparing the treatment of T40214/PEI (10mg/kg+2.5mg/kg), a lower drug dose of TEL03 (2mg/kg) simply given to mice has strong drug efficacy *in vivo*. After the treatments tumors were harvested. The western blots from the obtained tumors showed (Fig.B15B) that TEL03 inhibited both HIF-1 α and p-Stat3, and suppressed the expression of VEGF, but did not inhibit HIF-1 β , p300 and T-State3, consistent with the observation in cells.

(2) The mice bearing pancreatic tumors were treated in two groups: Group 1 was untreated; Group 2 was treated by TEL03 (2mg/kg) for 10 days and then monitored the tumor growth without treatment for another 9 days. Over 19 days the mean tumor volume in untreated mice increased from 225 to 754 mm³; in contrast, the mean tumor volume in TEL03-treated mice was decreased from 246 to 75 mm³ (Fig.B15C). At the endpoint, the mean tumor weight of untreated mice was 0.5 ± 0.05g whereas the mean tumor weight of TEL03-treated mice was 0.06 ± 0.01g (Fig.B14E). The results showed that after given with 2mg/kg of TEL03 in 6 times, the mean tumor volume of pancreatic tumors was dramatically suppressed and the tumors did not re-grow after stopping treatment in 9 days. The body weight of the treated mice was not affected by TEL03 treatment (Fig.B15D). Together, the agent TEL03 demonstrated greater-than-expected *in vivo* potency since this inhibitor has the ability to promote drug efficacy, reduce emergence of therapy-




Fig.B15. (A) Plots of mean tumor volumes (mm³) of breast tumors Vs days of drug treatment. (B) Western blots. (C) Plot of mean tumor volumes (mm³) Vs days of drug treatment. (D) Plot of mean body weight (g) Vs days of drug treatment. (E) The pictures in left and right show the mice bearing tumors without treatment and with TEL03-treated, respectively.

resistant cancer cells, and decrease the incidence of cancer relapse without introducing additional toxic side effects. Thus, targeting both HIF-1 α and Stat3 is considered as a promising strategy for breast cancer therapy.

C. CONCLUSION

Our main goal is to develop novel therapeutic agents from Chinese herbal medicine (CHM) that targets HIF-1 α /2 α for prostate cancer therapy. Hypoxia orchestrated by HIF-1 α is crucial for tumor progression, therapy resistance, and poor patient outcome. Also, HIF-1 α regulates several critical pathways in human cancers, including PI3K, AKT and MEK/ERK pathways. Overexpression of HIF-1 α in breast tumors not only strongly enhances the tumor growth rate and metastatic potential, but also contributes to resistance to radiotherapy and chemotherapy, and is associated with treatment failure and increased patient mortality. Stat3 participates in oncogenesis through the upregulation of genes encoding anti-apoptosis, cell-cycle regulators, and inducers of angiogenesis in many cancers, including breast cancer. Also, Stat3 signaling is a major intrinsic pathway of cancer inflammation and mediates the cancer-promoting properties. Stat3 suppresses anti-tumor immune responses and promotes inflammation-induced cancer, making it as a critical target for cancer therapy.

Recently, we have identified a perylene derivative TEL03 from *hypocrellin* (CHM: *Hypocrella bambusae*) that significantly inhibits activations of HIF-1 α /2 α and p-Stat3, and blocks the expression of their down-regulated oncogenes (e.g. Bcl2, VEGF, Glut1, and others) in cancer cells. TEL03 also dramatically suppressed the growth of prostate, breast and pancreatic tumors in xenograft models. Our previous studies provided evidence that targeting both HIF-1 α and Stat3 together could improve tumor response to either agent alone, and reduce drug resistance and treatment failure. TEL03 was showed inhibition of tumor growth and a marked delay in tumor re-growth, and demonstrated a greater-than-expected *in vivo* potency. Our results also provided evidence that TEL03 has potential to be a potent anti-cancer agent for pancreatic cancer therapy, suggesting that TEL03 could have a possible clinical application in prostate cancer therapy.

D. OVERALL PROJECT SUMMARY

The title of this idea development project is: Development of a combination therapy for prostate cancer by targeting Stat3 and HIF-1 α , which was founded for three years (7/2010-6/2013).

In this three-year period, (1) we have originally proposed the hypothesize that activation of Stat3 and HIF-1 strongly influence progression of prostate cancer, using a strategy that targets both Stat3 and HIF-1 α could produce an effective treatment for prostate cancer. Our systemic results demonstrated (28) that a combination treatment of T40214 (a Stat3 inhibitor) and JG244 (HIF-1 α inhibitor) to target both p-Stat3 and HIF-1 α together significantly induces cancer cell apoptosis and greatly enhances *in vivo* drug efficacy as compared with single agent that blocks activation of either p-Stat3 or HIF-1 α molecule alone. The combination treatment including a HIF-1 α /2 α inhibitor (JG244) not only has therapeutic efficacy in targeting HIF-1 α /2 α , but also could reduce the hypoxia-induced drug resistance to other therapies and enhance drug efficacy. **Our studies demonstrated that (i) the combination treatment by targeting both Stat3 and HIF-1 α together could make prostate cancer treatments more effective; and (ii) a combination treatment including a HIF-1 α inhibitor could be a pioneer strategy for prostate cancer therapy.**

(2) Based on our first studies, we have developed TEL03, a dual-inhibitor that targets both HIF-1 α /2 α and p-Stat3 for treatment of prostate and other cancers. TEL03, which is a novel anti-cancer agent derived from Chinese herbal medicine (CHM: *Hypocrella bambusae*), can promote drug efficacy, reduce emergence of therapy-resistant cancer cells, and decrease the incidence of cancer relapse with a low toxicity. CHM focuses on restoring a balance of energy, body, and spirit to maintain health rather than treating a particular diseases or medical condition. Also, they can help ease the side effects of

standard cancer treatment, control pain, improve quality of life, strengthen the immune system, and in some cases, stop tumor growth and spread. Therefore, TEL03 has a potential to be a novel clinical application in prostate cancer therapy. **These studies provided some critical information: (i) a dual inhibitor that targets both HIF-1 α and Stat3 simultaneously could be improve tumor response, reduce drug resistance and treatment failure; and (ii) anti-cancer agents obtained from CHM could have promising drug efficacy for prostate cancer therapies.**

(3) There still have more works need to do for developing a potent therapeutic agent for prostate cancer therapy when three years passed, such as: (I) to optimize TEL03 in order to make the agent more efficiency by performing medicinal chemistry and QSAR studies; (II) to test more in vivo studies, including different prostate cancer tumors, such as DU145 tumor that highly resists clinical drug treatment, and perform the cooperated *in vivo* efficacy in combination treatment using clinic drugs (e.g. docetaxel and others) with TEL03 to determine whether TEL03 has a great potential for clinical usage; and (III) screen more new compounds from CHM to discover a high potent inhibitor.

E. OVERALL PROJECT OUT COMES

Publications relevant to the project in this period:

1. Reddy KR, Guan Y, Qin G, Zhou Z, Jing N. "Combined treatment targeting HIF-1 α and Stat3 is a potent strategy for prostate cancer therapy" *Prostate* (2011) 16:1796-809.
2. Jing N. "Rational design of DNA anti-cancer agent that target signal transducer and activator of transcription (Stat3) for cancer therapy" *Book: CELL SIGNALLING and MOLECULAR TARGETS IN CANCER*. Springer Science LLC 2012:167-190.
3. Chen H, Guan Y, Yuan G, Tweardy DJ, Jing N. "A perylene derivative TEL03 targets HIF-1 α and Stat3 for cancer therapy" *In press* (2013).

Patent application (collaboration between China and Jing).

1. Chinese patent (pending, 2012): Perking University, Jing N (BCM), Guan Y (BCM). "二萜嵌苯衍生物作为p-STAT3/Hif1 α 信号传导通路抑制剂在相关疾病中的应用" (application of perylene derivatives that inhibit p-Stat3/HIF-1 α in medical diseases) (the contributions of Baylor College of Medicine (BCM), USA, and Perking University, China, are 50:50).

Abstracts presented in conferences.

1. Reddy KR, Guan Y, Jing N. Combination of targeting HIF-1 α and Stat3 is a potent strategy for prostate cancer therapy. AACR-NCI-EORT, November, 2010.
2. Chen H, Guan Y, Yuan G, Tweardy DJ, Jing N. TEL is a novel dual anti-cancer agent that targets Stat3 and HIF-1 α . AACR-NCI-EORT, November 2011.

E. REFERENCES

1. Abouhard, S., Corn, PG. Optimal therapy sequencing in metastatic castration-resistance prostate cancer. *Curr Oncol Rep* DOI 10.1007, 2013.
2. Marignol, L., Coffey, M., Lawler, M., Hollywood, D. Hypoxia in prostate cancer: a powerful shield against tumour destruction. *Cancer Treatment Reviewer*, 34: 313-327, 2008.
3. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative molecular concept modeling of prostate cancer progression. *Nat Genet*. 39: 1159-1166, 2007.
4. Thews o, Gassner B, Kelleher DK, Schwerdt G, Gekle M. Impact of hypoxia and acidic extracellular conditions on cytotoxicity of chemotherapeutic dtugs. *Adv Exp Med Biol* 599: 155-161, 2007.

5. Semenza, G. L., Neufeldt, M. K., Chi, S. M., and Antonarakis, S. E. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. *Proc Natl Acad Sci U S A*, 88: 5680-5684, 1991.
6. Semenza, G. L. and Wang, G. L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. *Mol Cell Biol*, 12: 5447-5454, 1992.
7. Melillo, G. Hypoxia-inducible factor 1 inhibitors. *Methods Enzymol*, 435: 385-402, 2007.
8. Onnis, B., Rapisarda, A., and Melillo, G. Development of HIF-1 inhibitors for cancer therapy. *J Cell Mol Med*, 13: 2780-2786, 2009.
9. Wang, G. L., Jiang, B. H., Rue, E. A., and Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci U S A*, 92: 5510-5514, 1995.
10. Wang, G. L. and Semenza, G. L. Purification and characterization of hypoxia-inducible factor 1. *J Biol Chem*, 270: 1230-1237, 1995.
11. Gruber, M. and Simon, M. C. Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. *Curr Opin Hematol*, 13: 169-174, 2006.
12. Hirota, K. and Semenza, G. L. Regulation of angiogenesis by hypoxia-inducible factor 1. *Crit Rev Oncol Hematol*, 59: 15-26, 2006.
13. Semenza, G. L. Oxygen sensing, homeostasis, and disease. *N Engl J Med*, 365: 537-547.
14. Chun, Y. S., Adusumilli, P. S., and Fong, Y. Employing tumor hypoxia for oncolytic therapy in breast cancer. *J Mammary Gland Biol Neoplasia*, 10: 311-318, 2005.
15. Patiar, S. and Harris, A. L. Role of hypoxia-inducible factor-1 α as a cancer therapy target. *Endocr Relat Cancer*, 13 Suppl 1: S61-75, 2006.
16. Buettner, R., Mora, L. B., and Jove, R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. *Clin Cancer Res*, 8: 945-954, 2002.
17. Jing, N. and Tweardy, D. J. Targeting Stat3 in cancer therapy. *Anticancer Drugs*, 16: 601-607, 2005.
18. Becker, S., Groner, B., and Muller, C. W. Three-dimensional structure of the Stat3 β homodimer bound to DNA. *Nature*, 394: 145-151, 1998.
19. Braunstein, J., Brutsaert, S., Olson, R., and Schindler, C. STATs dimerize in the absence of phosphorylation. *J Biol Chem*, 278: 34133-34140, 2003.
20. Chen, X., Vinkemeier, U., Zhao, Y., Jeruzalmi, D., Darnell, J. E., Jr., and Kuriyan, J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. *Cell*, 93: 827-839, 1998.
21. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science*, 264: 1415-1421, 1994.
22. Silvennoinen, O., Schindler, C., Schlessinger, J., and Levy, D. E. Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. *Science*, 261: 1736-1739, 1993.
23. Levy, D. E. and Darnell, J. E., Jr. Stats: transcriptional control and biological impact. *Nat Rev Mol Cell Biol*, 3: 651-662, 2002.
24. Bowman, T., Garcia, R., Turkson, J., and Jove, R. STATs in oncogenesis. *Oncogene*, 19: 2474-2488, 2000.
25. Yu, H. and Jove, R. The STATs of cancer--new molecular targets come of age. *Nat Rev Cancer*, 4: 97-105, 2004.
26. Yu, H., Kortylewski, M., and Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. *Nat Rev Immunol*, 7: 41-51, 2007.
27. Yu, H., Pardoll, D., and Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat Rev Cancer*, 9: 798-809, 2009.

28. Reddy KR, Guan Y, Qin G, Zhou Z, Jing N. Combined treatment targeting HIF-1 α and Stat3 is a potent strategy for prostate cancer therapy. *Prostate*, 2011; 71: 1796-1809 [PMID: 21480310].
29. Buettner, R., Mora, L. B., and Jove, R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. *Clin Cancer Res*, 2002; 8: 945-954.
30. Bowman, T., Garcia, R., Turkson, J., and Jove, R. STATs in oncogenesis. *Oncogene*, 2000; 19: 2474-2488 (review).
31. Yu, H. and Jove, R. The STATs of cancer--new molecular targets come of age. *Nat Rev Cancer*, 2004; 4: 97-105 (review).
32. Yu, H., Kortylewski, M., and Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. *Nat Rev Immunol*, 2007; 7: 41-51 (review).
33. Yu, H., Pardoll, D., and Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat Rev Cancer*, 2009; 9: 798-809 (review).
34. Jing, N., Li, Y., Xiong, W., Sha, W., Jing, L., and Twardy, D. J. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. *Cancer Res*, 2004; 64: 6603-6609. <http://cancerres.aacrjournals.org/cgi/reprint/64/18/6603>
35. Jing, N., Li, Y., Xu, X., Sha, W., Li, P., Feng, L., and Twardy, D. J. Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. *DNA Cell Biol*, 2003; 22: 685-696.
36. Dames, S. A., Martinez-Yamout, M., De Guzman, R. N., Dyson, H. J., and Wright, P. E. Structural basis for Hif-1 α /CBP recognition in the cellular hypoxic response. *Proc Natl Acad Sci U S A*, 2002; 99: 5271-5276.
37. Chakraborty, A. and Twardy, D. J. Stat3 and G-CSF-induced myeloid differentiation. *Leuk Lymphoma*, 1998; 30: 433-442.
38. Shao, H., Xu, X., Mastrangelo, M. A., Jing, N., Cook, R. G., Legge, G. B., and Twardy, D. J. Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif. *J Biol Chem*, 2004; 279: 18967-18973.
39. Xu, X., Kasembeli, M. M., Jiang, X., Twardy, B. J., and Twardy, D. J. Chemical probes that competitively and selectively inhibit Stat3 activation. *PLoS One*, 2009; 4: e4783.
40. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. *Crit Rev Oncol Hematol*, 2006; 59: 15-26 (review).

GENERAL BIOGRAPHICAL INFORMATION

A. Personal

Name: Naijie Jing

B. Education:

- a. Undergraduate Education:
Huaiyin Normal University, Jiansu Province, China, B.S, 1981
- b. Medical Education or Graduate Education
The University of Alabama at Birmingham, Alabama, M.S. (Biophysics), 1988
The University of Alabama at Birmingham, Alabama, Ph.D. (Biophysics), 1994
- c. Postgraduate Training:
Postdoctoral Fellow, Laboratory of Molecular Biophysics, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, Mentor: Dan W. Urry, 1994 – 1995

Postdoctoral Associate, Department of Molecular Physiology and Biophysics, Baylor College of Medicine Houston, TX, Mentor: Michael E. Hogan, 1995 – 1998

C. Academic Appointments:

- a. Current Faculty Position:
Associate Professor, Section of Infectious Diseases, Department of Medicine
Baylor College of Medicine, Houston, Texas, 2005 – present.

Faculty members in Cancer Center, AIDS Center and Keck Center of Computational and Structural Biology
Baylor College of Medicine, Houston Texas, 2001-present
- b. Previous faculty position at other institutions:
Assistant Professor, Section of Infectious Diseases, Department of Medicine
Baylor College of Medicine, Houston, Texas, 2001 – 2005.

Assistant Professor, Department of Molecular Physiology and Biophysics
Baylor College of Medicine, Houston, Texas 1999 – 2001

Instructor, Department of molecular Physiology and Biophysics
Baylor College of Medicine, Houston, Texas 1998 – 1999

II. RESEARCH INFORMATION

A. Research Supports

Funded Awarded

- a. Title: Development of a combination therapy for prostate cancer by targeting Stat3 and HIF-1 α .
- b. Funding Agency: Department of Defense/ US Army, PC093258.
- c. PI: Naijie Jing
- d. Dates of Funding: 7/1/20010 -6/30/2013.
- e. Grant or Contract: DOD Grant.
- a. Title: A novel inhibitor of Stat3 for prostate cancer therapy
- b. Funding Agency: National Institute of Health/NCI, CA104035.
- c. PI: Naijie Jing
- d. Dates of Funding: 4/1/2005 – 2/28/2011
- e. Grant or Contract: NIH R01Grant
- a. Title: GQ-ODN T40214: A novel and potent anti-cancer agent for prostate cancer therapy
- b. Funding Agency: Prostate Cancer Foundation
- c. PI: Naijie Jing
- d. Dates of Funding: 3/1/2007 –2/28/2008

- e. Grant or Contract: PCF Competitive Award.
- a. Title: A novel strategy of chemotherapy for head and neck with GQ-ODN, a novel anti-cancer agent.
- b. Funding Agency: NIH/NCI/SPORE of Head and Neck in MD Anderson, CA097007.
- c. Project PI: Naijie Jing
- d. Dates of Funding: 3/1/2005 – 2/28/2007
- f. Grant or Contract: NIH Development Grant
- a. Title: A novel strategy of chemotherapy for head and neck with GQ-ODN, a novel anti-cancer agent.
- b. Funding Agency: NIH/NCI/SPORE of prostate cancer in Baylor, CA058204.
- c. Project PI: Naijie Jing
- d. Total Dates of Funding: 9/1/2005 – 8/31/2007
- e. Grant or Contract: NIH Development Grant
- a. Title: Targeting Stat3 with G-quartet oligonucleotides in metastatic prostate cancer
- b. Funding Agency: Department of Defense/ US Army, PC020407.
- c. PI: Naijie Jing
- d. Dates of Funding: 4/1/2003 -3/31/2006
- e. Grant or Contract: DOD Grant.
- a. Title: Developing a potent inhibitor of HIV-1 integrase
- b. Funding Agency: NIH/GM, GM 60153
- c. PI: Naijie Jing
- d. Dates of Funding: 9/1/1999 – 8/31/2003
- e. Grant or Contract: NIH R01Grant.

B. National and International Scientific Participation:

- a. Journal editorial boards:
 - Editorial Board, *Current Molecular Pharmacology*.
 - Guest Editor, *Current Pharmaceutical Design*.
 - Editor Board, *Recent Patent Reviews on Anti -Cancer Drug Discovery*
 - Editorial Board, *Clinical Pharmacology: Advances and Applications*.
- b. Professional societies:
 - Overseas Fellow of Royal Society of Medicine (London, England)
 - Member of American Chemical Society (ACS)
 - Member of American Association for the Advancement of Science (AAAS)
 - Member of New York Academy of Science
 - Member of American Associate of Cancer Research (AACR)
- c. Study section.
 - ZRG1 OTC-X (02) Translational Clinical Oncology, NCI/NIH, 2011
 - ZRG1 OTC-X (90) Cancer Therapeutics AREA Grant Applications Study Section, 2012

C. Patents approved and issued:

I. US patents:

1. **Jing, N.** et al., “A Novel Technology of Intracellular Delivery of DNA Oligonucleotides to Improve Drug Activity” USPTO Application#:2006199777.
2. **Jing N** and Guan Y “G-Quartet oligonucleotides that target hypoxia-induced factor 1- α (HIF1 α)” USPTO Application #: 20090075928.

II. Chinese patent (pending, 2012):

1. Yuan G, **Jing N**, Chen H, Guan Y. “二萜嵌苯衍生物作为 p-STAT3/Hif1 α 信号传导通路抑制剂在相关疾病中的应用” (application of perylene derivatives that inhibit p-Stat3/HIF-1 α in medical diseases) (the contributions of Baylor college of Medicine, USA, and Perking University, China, are 50:50).

D. Publications:

a. Full papers (published in referred journals):

1. Dan W. Urry, **Naijie Jing**, and K. U. Prasad, "On the Mechanism of Channel-Length Dependence of Gramicidin Single-Channel Conductance", (1987) *Biochimica et Biophysica Acta* 902:137-144.

2. Dan W. Urry, **Naijie Jing**, Tina L. Trapane, Chi-Hao Luan, and Marsh Waller, "Ion Interaction with the Gramicidin A Transmembrane Channel: Cesium-133 and Calcium-43 NMR Studies", (1988) *Current Topics in Membrane and Transport* 33:51-90.
3. Dan W. Urry, D. Channe Gowda, Shaoqing Peng, Timoty M. Parker, **Naijie Jing**, and R. Dean Harris, "Monometric Design of Extraordinary Hydrophobicity-induced pKa Shifts for Aspartic Acid: Relevance to Protein Mechanisms", (1994) *Biopolymers* 34:889-896.
4. **Naijie Jing**, Kari U. Prasad, and Dan W. Urry, "NMR Determination of Conformation of Ion-Transport-Competent Gramicidin in DPC Micelles: A Right-Handed, Head-to-Head Dimerized, Single-Stranded $\beta^{6.3}$ -Helix", (1994) *Biophysical J.* 66(2): A353.
5. Dan W. Urry, D. T. McPherson, J. Xu, H. Daniell, C. Guda, D. C. Gowda, **Naijie Jing**, T. M. Parker, "Protein-Based Polymeric Material: Syntheses and Properties" (1995) in *The Polymeric Materials Encyclopedia: Sythesis, Properties and Applications*, CRC Press, Boca Raton, pp. 2645-2699.
6. **Naijie Jing**, Kari U. Prasad, and Dan W. Urry, "The Determination of Binding Constants of Micellar Packaged Gramicidin A by ^{13}C and ^{23}Na NMR", (1995) *Biochimica et Biophysica Acta* 1238: 1-11.
7. **Naijie Jing** and Dan W. Urry, "Ion Pair Binding of Ca^{++} and Cl^- Ions in Micellar-Packaged Gramicidin A", (1995) *Biochimica et Biophysica Acta* 1238: 12-21.
8. D. G. Gowda, C. H. Luan, R. L. Furner, S. Q. Peng, **N. Jing**, C. M. Harris, T. M. Parker, and D. W. Urry "Synthesis and Characterization of the Human Elastin W4 Sequence", (1995) *International Journal of Peptide & Protein Research* 46:453-463, 1995.
9. Dan W. Urry, Larry C. Hayes, D. Channe Gowda, Shao Qing Peng and **Naijie Jing**, "Electro-Chemical Transduction in Elastic Protein-Based Polymers: A Model for an Energy Conversion Step of Oxidative Phosphorylation" (1995) *Biochemical Biophysical Research Communication* 210(3): 1031-1039.
10. Dan W. Urry, Asima Pattanaik, Mary Ann Accavitti, Chi-Xiang Laun, David T. McPherson, Jie Xu, D. Channe Gowda, Timothy M. Parker, Cynthia M. Harris, and **Naijie Jing** "Transductional Elastic and Plastic Protein-Based Polymers as Potential Medical Devices" (1996) in *Handbook of Biodegradable Polymers* (eds. Domb, Kost, and Wiseman) by Harwood Academic Publishers, Chur, Switzerland, 2412-2429.
11. **Naijie Jing**, Robert F. Rando, Yves Pommier, and Michael E. Hogan "Ion Selective Folding of Loop Domains in a Potent Anti-HIV Oligonucleotide" *Biochemistry* (1997) 36: 12498-12505.
12. **Naijie Jing**, Xiaolian Gao, Robert F. Rando, and Michael E. Hogan "Potassium-Induced loop Conformational Transition of a Potent Anti-HIV Oligonucleotide" *Journal of Biomolecular Structure and Dynamics* (1997) Vol.15(3): 573-585.
13. **Naijie Jing** and Michael E. Hogan "Structure-Activity of Tetrad-forming Oligonucleotide as a Potent Anti-HIV Therapeutic Drug" *The Journal of Biological Chemistry* (1998) 273 (52): 34992-34999.
14. **Naijie Jing**, De, Clercq, E., Rando, R. F., Pallansch, L., Lackman-Smith, C., Lee, S., and Hogan, M. E. "Stability-Activity Relationships of a Family of G-tetrad forming Oligonucleotides as Potent HIV Inhibitors: A Basis for Anti-HIV Drug Design" *The Journal of Biological Chemistry* (2000) 275 (5): 3421-3430.
15. **Naijie Jing**, Marchand, C., Liu, J., Mitra, R., Hogan, M. E., and Pommier, Y. "Mechanism of Inhibition of HIV-1 Integrase by G-tetrad Forming Oligonucleotides *in Vitro*" *Journal of Biological Chemistry* (2000) 275 (28), 21460-21467.
16. **Naijie Jing** "Developing G-quartet oligonucleotides as novel anti-HIV agents: focus on anti-HIV drug design" *Expert Opinion on Investigational Drugs* (2000) 9(8) 1777-1785.
17. **Naijie Jing**, Xuejun Xu "Rational Drug Design for DNA Oligonucleotides as Potent HIV Inhibitors" *Current Drug Targets-Infectious Disorder* (2001) 1(2), 79-90.
18. **Naijie Jing**, Marchand, C., Guan, Y., Liu, J., Pallansch, L., Lackman-Smith, C., De Clercq, E. and Pommier, Y. "Structure-activity of Inhibition of HIV-1 Integrase and Virus Replication by G-quartet Oligonucleotides" *DNA and Cell Biology* (2001) 20(8), 499-508.
19. Marchand, C., Pourquier, P., Laco G., **Jing, N.** and Pommier, Y. "interaction of Human Nuclear Topoisomerase with Guanosine-quartet-forming and Guanosine-rich Single-stranded DNA and RNA oligonucleotides" *The Journal of Biological Chemistry* (2002) 277(11), 8906-8911.
20. **Naijie Jing**, Xiong, W., Guan, Y., Pallansch, L., Wang S. "Potassium Dependent Folding: A Key to Intracellular Delivery of G-quartet Oligonucleotides as HIV Inhibitors" *Biochemistry* (2002) 41(17), 5397-5403.
21. **Naijie Jing**, Li, Y., Xcu, X., Li, P., Feng, L., Tweardy, D. "Targeting Stat3 with G-quartet oligonucleotides in human cancer cells" *DNA and Cell Biology* (2003) 22, 685-696.

22. Shao, H., Xu, X., Mastrangelo, M.-A., **Jing, N.**, Cook, R. G., Legge, G. D., and Twardy, D. J. "Structural requirements for Stat3 binding to phosphotyrosine ligands containing the YXXQ motif" *Journal of Biological Chemistry* (2004) 279, 18967-18973.
23. Watanabe, S., Mu, W., Kahn, A., **Jing, N.**, Li, J. H., Lan, H. Y., Nakagawa, T., Ohashi, R., Johnson, R. J. "Role of JAK/STAT pathway in IL-6 induced activation of vascular smooth muscle cells" *Am. J. Nephrology* (2004) 24, 387-392.
24. **Naijie Jing**, Li, Y., Xiong, W., Sha, W. Jing, L. Twardy, D. J. "G-quartet oligonucleotides: a new class of Stat3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis" *Cancer Research* (2004) 64, 6603-6609.
25. **Jing, N.** Sha, W., Li, Y., Xiong, W., Twardy, D. J. "Rational drug design of G-quartet DNA as anti-cancer agents" *Curr. Pharma. Design* (2005) 11, 2841-2854.
26. **Jing, N.** and Twardy, D. J. "Targeting Stat3 in cancer therapy", an invited review article. *Anti-cancer Drugs* (2005) *Anti-Cancer Drugs* (2005) 16, 601-607.
27. Shao, H. Xu, X., **Jing, N.**, Twardy, D. J. "Structure requirements for signal transducer and activator of transcription (STAT) 3 binding to granulocyte colony-stimulating factor receptor (G-CSFR) phosphotyrosine ligands 704 and 744" *Journal of Immunology* (2006) 176:2933-41.
28. **Jing N**, Zhu Q, Yuan P, Li Y, Mao L, Twardy DJ. "Targeting Stat3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer" *Mol. Cancer Therapeutics*. (2006) 5:279-286.
29. Nussenzveig RH, Lingam HB, Gaikwad A, Zhu Q, **Jing N**, Prchal JT. "A novel mutation of the cytochrome-b5 reductase gene in an Indian patient: molecular basis of type I methemoglobinemia" *Haematologica/the hematology journal* (2006) 91:1544-1547.
30. Twardy, DJ, **Jing N.** "Enhancing or eliminating signals for cell survival to treat disease" *Transactions of the American Clinical and climatological Associate* (2006) 117: 33-52.
31. Weerasinghe P, Garcia GA, Zhu q, Yuan P, Feng L, Mao L, **Jing N.** "Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides" *International Journal of Oncology* (2007) 31:129-136.
32. Zhu Q and **Jing N.** "Computational Study on Mechanism of G-Quartet Oligonucleotide T40214 Selectively Targeting Stat3" *Journal of Computer-Aided Molecular Design* (2007) 21:641-648.
33. Weerasinghe P, Li Y, Guan Y, Zhang R, Twardy DJ, **Jing N.** "T40214/PEI complex, a potent threapeutics for prostate cancer that targets Stat3 signaling" *Prostate* (2008) 68:1430-1442.
34. Zhou Z, Bernardo A, Zhu Q, Guan Y, Sun W, Lopex JA, **Jing N**, Dong JF. "A G-quartet oligonucleotide blocks glycoprotein Ib-mediated platelet adhesion and asgregation under flow conditions" *Thrombosis and Haemostasis* (2009) 102:529-537.
35. Guan Y, Reddy KR, Yang D, Zhu Q, Li Y, Lee KA, Weerasinghe P, Prchal J, Semenza GL, **Jing N.** "G-rich Oligodeoxynucleotides Inhibit HIF-1 α and HIF-2 α and Block Tumor Growth" *Molecular Therapy* (2010) 18:188-197.
36. Reddy KR, Guan Y, Qin G, Zhou Z, **Jing N.** "Combined treatment targeting HIF-1 α and Stat3 is a potent strategy for prostate cancer therapy" *Prostate* (2011) 16:1796-809.
37. **Jing N.** "Rational design of DNA anti-cancer agent that target signal transducer and activator of transcription (Stat3) for cancer therapy" *Book: CELL SIGNALLING and MOLECULAR TARGETS IN CANCER*. Springer Science LLC 2012:167-190.
38. Zhou Z, Bolgiano D, Salsbery B, **Jing N**, Wu X, Vijayan V, Rumbaut R, Lopez J, Dong JF. Stat 3 regulate collagen-induced platelet aggregation independent to its transcription factor activity. *Circulation* (2013)127:476-485.
39. Chen H, Guan Y, Yuan G, Twardy DJ, **Jing N.** "A perylene derivative TEL03 that targets both HIF-1 α and Stat3 for cancer therapy" *in press* (2013).
40. Hillion J, Belton A, Shah S, Turson J, **Jing N**, Twardy D, Di Cello F, Huso D, Resar LMS. "Nanoparticle delivery of inhibitory Stat3 GQ-oligonucleotides blocks tumor growth in an HMGA1transgenic model of T-cell leukemia" submitted (2013).

b. Abstracts given during last five years:

1. **Naijie Jing**, Li, Y., Xcu, X., Li, P., Feng, L., Twardy, D. "Inhibition of Stat3 activity by G-quartet oligodeoxynucleotides." 94th AACR meeting, 2003, Washington, DC.
2. Shao H, **Jing, N.** and Twardy, D. J.. "Structural requirements for design of peptidomimetics targeting Stat3 activation by the EGFR" 94th AACR meeting, 2003, Washington, DC.
3. **Jing, N.** Sha, W., Li, Y., Xiong, W., Twardy, D. J. "Rational drug design of G-quartet DNA as anti-cancer agents" Molecular Target and Cancer Therapeutic, EORTC-NCI-AACR meeting, 2003, Boston, MA.

4. **Naijie Jing***, Li, Y., Xiong, W., Sha, W. Jing, L. Tweardy, D. J. "G-quartet oligonucleotides: a new class of Stat3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis" 95th AACR conference, 2004.
5. **Naijie Jing***, Yidong Li, Wei Sha, Weijun Xiong, David J. Tweardy "A novel strategy to inhibit Stat3 signaling for human cancer therapy" Molecular Target and Cancer Therapeutic, EORTC-NCI-AACR meeting, 2004.
6. **Naijie Jing***, Yidong Li, Weijun Xiong, Wei Sha, Ling Jing, David J. Tweardy "G-Quartet Oligonucleotides: A new class of Stat3 inhibitors for cancer therapy" 2nd Cancer Center symposium, 2004, Baylor College of Medicine.
7. **Naijie Jing***, Yidong Li, Qiqing Zhu, Ping Yuan, Yun Oh, Li Mao and David J. Tweardy "Suppression of growth of squamous cell carcinoma of head and neck xenografts in nude mice by G-quartet oligonucleotides that target Stat3" 96th AACR conference April 16-21, 2005, Anaheim CA.
8. Qiqing Zhu, Yidong Li, and **Naijie Jing*** "Structure-based drug design of G-quartet Oligonucleotides as a new class of Stat3 inhibitors for cancer therapy" 96th AACR conference April 16-21, 2005, Anaheim CA.
9. **Jing N**, Zhu Q, Li Y, Weerasinghe Y. "Targeting Stat3 with G-quartet Oligonucleotides: A Potential Novel Therapy for Human Cancers" EORTC-NCI-AACR meeting, 2005, Philadelphia, PN.
10. Weerasinghe P, Garcia GE, Yuan P, Feng L, Mao L, **Jing N**. "Targeting Stat3 with GQ-ODN: A Novel Strategy for Non-small Cell Lung Cancer Therapy" 97th AACR conference April 1-5, 2006, Washington, DC.
11. **Jing N**. "Targeting Stat3 with G-quartet oligonucleotides: a novel therapeutic strategy for human cancers" The 11th World Congress on Advances in Oncology and 9th International Symposium on Molecular Medicine. October 12-14, 2006, Hersonissos, Crete, Greece.
12. Weerasinghe P, Li Y, Guan Y, Tweardy DJ, **Jing N** "A novel strategy for cancer therapy by targeting Stat3 with G-quartet oligonucleotides" 4th Annual Conference on Cancer Drug research & development. February 8-9, 2007, Philadelphia, PA.
13. **Jing N**, Weerasinghe P, Li Y, Zhu Q, Guan Y. "A Novel Strategy for Prostate Cancers Therapy by Targeting Stat3 with G-quartet Oligonucleotides" Innovative Minds in Prostate Cancer Today (IMPACT) meeting, Atlanta GE, Sept.6-8, 2007.
14. **Jing** et al. A Novel Strategy for Prostate Cancers Therapy by Targeting Stat3 with G-quartet Oligonucleotides. 14th Prostate Cancer Foundation Scientific Retreat Oct, Lake Tahoe, NE 11-13, 2007.
15. Yongli Guan, Qiqing Zhu, Yifei Li, Priya Weerasinghe, Kavitha Ramasamy Reddy, Josef Prchal and **Naijie Jing**. Novel G-quartet Oligonucleotides Inhibit HIF-1 α and HIF-2 α Activity and Suppress Growth of Pancreatic and Prostate Tumors. AACR-NCI-EORT, Oct, 22-28, 2007.
16. **Naijie Jing**. Novel anti-cancer agents for cancer therapy. International Drug Discovery Science and Technology (IDDST), Xi'an, China, Nov,7-13,2007.
17. Zhou Zhou^{1,3}, Aubrey Bernado⁴, Yongli Guan², Chalmette Ball¹, **Naijie Jing**², Jing-fei Dong^{1,3}. G-QUARTET OLIGONUCLEOTIDE T30923 BLOCKS GP IB-VWF MEDIATED PLATELET AGGREGATION UNDER STATIC AND FLOW CONDITIONS. AHS, DEC, 20, 2007.
18. Guan Y, Reddy KR, Yang D, Zhu Q, Li Y, Lee KA, Weerasinghe P, Prchal J, Semenza GL, **Jing N**. G-rich Oligodeoxynucleotides Inhibit the levels of HIF-1 α and HIF-2 α and Block Tumor Growth. 100th AACR annual meeting, April 18-22, 2009.
19. Reddy KR, Guan Y, **Jing N**. Combination of targeting HIF-1 α and Stat3 is a potent strategy for prostate cancer therapy. AACR-NCI-EORT, November, 2010.
20. Chen H, Guan Y, Yuan G, Tweardy DJ, **Jing N**. TEL is a novel dual anti-cancer agent that targets Stat3 and HIF-1 α . AACR-NCI-EORT, Nov.12– 16, 2011.